Identifying severe COVID-19 risk variants modulating enhancer reporter activity in lung cells.

Publication date: Jul 17, 2026

Common genetic variants contribute to risk for complex human diseases. However, despite thousands of associations, variants modulating disease risk and their functional impact remain largely unknown. This includes SARS-CoV-2 infection, where outcomes range from asymptomatic to fatal. Most genetic risk variants associated with COVID-19 disease, identified through genome wide association studies, are located in the non-coding genome and may function by altering gene expression in disease-relevant cells and tissues. To address this at scale, we tested >4800 severe COVID-19-associated variants to determine the impact of individual variants and variant combinations on regulatory activity using Self-Transcribing Active Regulatory Region sequencing, a massively-parallel reporter assay. Focusing on variants that may have their impact in the lung, in a lung epithelial cell line (A549) we identify 166 variants within active sequences, of which 29 modulate activity allele-specifically. Evaluating variant combinations, we observe both additive and non-additive effects on regulatory activity. We employ state-of-the-art deep learning models to interpret allele-specific variant effects on regulatory activity and endogenous genomic features. Our work provides a set of prioritised severe COVID-19-associated variants that modulate regulatory activity in lung epithelial cells, candidate transcription factors, and candidate target genes with potential to be disease modifying.

Open Access PDF

Concepts Keywords
Activity
Cells
Covid
Disease
Genetic
Genome
Lung
Modulating
Non
Regulatory
Reporter
Risk
Severe
Variant
Variants

Semantics

Type Source Name
disease MESH COVID-19
pathway REACTOME SARS-CoV-2 Infection
disease MESH Cancer
disease MESH fac
disease MESH viral infection
disease MESH infection
disease MESH lung inflammation
drug DRUGBANK Chlordiazepoxide
disease MESH erythroleukemia
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH PCL
disease MESH death
disease MESH fibrosis
disease MESH acute respiratory distress syndrome
disease MESH coronavirus infection
disease MESH adenocarcinoma
disease MESH included
disease MESH AS1
pathway REACTOME mRNA Splicing
disease MESH cap
disease MESH melanoma
pathway KEGG Melanoma
disease MESH obesity
disease MESH Hirschsprung disease
disease MESH genome stability
disease MESH central obesity
disease MESH psychiatric disorders
disease MESH asthma
pathway KEGG Asthma
drug DRUGBANK Guanosine
disease MESH lung cancer
disease MESH atrial fibrillation
disease MESH severe acute respiratory syndrome
disease MESH critical illness
disease MESH Ito
disease MESH Alzheimer’s disease
disease MESH influenza
disease MESH superinfections
disease MESH CCO
drug DRUGBANK Papain
drug DRUGBANK Natural alpha interferon
disease MESH lung injury
drug DRUGBANK Bleomycin
disease MESH BLM
disease MESH respiratory diseases
disease MESH Allergy
disease MESH Dis
disease MESH bronchopulmonary dysplasia
disease MESH pulmonary fibrosis
disease MESH Pyl
drug DRUGBANK (S)-Des-Me-Ampa

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *